News Release
 

November 14, 2011

CONTACT: Jessica Mikulski
(C) 215-796-4829
Jessica.mikulski@uphs.upenn.edu

Perelman School of Medicine


This release is available online at
http://www.uphs.upenn.edu/news/News_Releases/2011/11/ni-meas-heart-failure/

Non-Invasive Measurement Identified as a Strong Predictor for Heart Failure in the General Population, Penn Study Shows

New Measurement a Stronger Indicator for Heart Failure Than
Hypertension and Other Established Risk Factors

Philadelphia –A new study from researchers at the Perelman School of Medicine at the University of Pennsylvania and collaborators at various institutions, presented at the 2011 American Heart Association Scientific Sessions, shows that a novel, non-invasive measurement of arterial wave reflections may be able to predict who is most at risk for heart failure. The authors presented data from an ancillary study of the Multi-Ethnic Study of Atherosclerosis (MESA).

When the heart contracts it generates a pulse or energy wave that travels through the arteries. This wave gets reflected in parts of the arterial tree and returns to the heart while it is ejecting blood, increasing the heart’s workload.  Increased wave reflections can lead to increased pressure on the heart and have been shown to be independent predictors of cardiovascular morbidity and mortality in populations with established heart disease or advanced kidney disease, but their association with adverse outcomes in the general population has remained unclear. Furthermore, the specific association between increased wave reflections and heart failure had not been shown before.

"Over five million people in the U.S. alone have heart failure, and it results in approximately 300,000 deaths each year.  It’s critical that we work to discover novel ways to identify patients most at risk," said Julio A. Chirinos, MD, assistant professor of Medicine at Penn and the study’s lead author.  "We show for the first time in a large general population that people with prominent arterial wave reflections are at greater risk for developing heart failure in the future."

In the current study, Dr. Chirinos and collaborators measured arterial wave reflections with a simple, non-invasive procedure known as arterial tonometry.  Arterial tonometry is a technique for blood-pressure measurement in which an array of pressure sensors is pressed against the skin over an artery. The researchers analyzed the radial artery pressure obtained at baseline from 5,958 participants in the Multi-Ethnic Study of Atherosclerosis (MESA) and assessed the relationship between the magnitude of the reflected wave at baseline and incident cardiovascular events (CVE) and congestive heart failure (CHF). All patients in the MESA cohort had no known cardiovascular disease at baseline. 

During median 6.46 years of follow-up in the current study, the researchers found that even just a 10 percent increase in wave reflection magnitude was predictive of a higher risk of combined cardiovascular events, hard cardiovascular events, and was strongly predictive of incident heart failure. This measure was a stronger predictor of CHF risk than hypertension and other established modifiable risk factors, as measured by established medical standards and population-based risks. This suggests that wave reflections are important determinants of heart failure risk.

"Although more experimental studies and clinical trials should be pursued to confirm a causal role, these findings interpreted in the context of available data, identify increased wave reflections as a new potential mechanistic risk factor for heart failure in the general population," said Dr. Chirinos. "We hope that this line of research has the potential to lead to therapeutic approaches for prevention of heart failure."

MESA is a longitudinal study of the characteristics of subclinical cardiovascular disease (disease detected non-invasively before it has produced clinical signs and symptoms) and risk factors that predict progression from subclinical to clinically cardiovascular disease, in a diverse population-based sample. Participants in MESA come from diverse race and ethnic groups, including African Americans, Latinos, Asians, and Caucasians.  MESA is sponsored by the National Heart, Lung, and Blood Institute of the National Institutes of Health.

###

Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $4.3 billion enterprise.

The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 17 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $392 million awarded in the 2013 fiscal year.

The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania -- recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report; Penn Presbyterian Medical Center; Chester County Hospital; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Chestnut Hill Hospital and Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine.

Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2013, Penn Medicine provided $814 million to benefit our community.